Dr. Michel J. Shami, MD

Dr. Shami practices at Texas Retina Associates in Lubbock, Texas.

Dr. Shami's NPI, 1780683227, was assigned on July 18, 2005. Dr. Shami graduated from American University of Beirut Faculty of Medicine in 1985. Dr. Shami holds Texas license H8830.

Dr. Shami's primary practice is Texas Retina Associates, at 4517 98th St, Lubbock, TX 79424 in Lubbock County. The practice phone is (806) 792-0066.

Dr. Shami's primary practice is Texas Retina Associates in Lubbock, Texas. Dr. Shami is also affiliated with Covenant Medical Center. Dmand AI also links Dr. Shami to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shami practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Shami's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dmand AI has Dr. Shami's licenses on file in 3 states: Texas, Kansas and Maryland.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, glaucoma, inflammation of iris, laser destruction of retinal or choroid lesions and retinal detachment among the conditions Dr. Shami treats.

CMS data shows 39,154 Medicare services from Dr. Shami across 16 procedure codes in 2024, for 1,109 Medicare patients. Medicare paid $2,048,838 for them.

CMS counts 1,109 Medicare patients who saw Dr. Shami in 2024. The largest group is 75 to 84, with 437 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Shami's median patient age at 73, with 58% women.

In 2024, Dr. Shami wrote 1,041 Medicare Part D claims for 307 patients. 69% of them were for generic drugs. CMS names the drug for 971 of them, across 15 drugs with 11 or more claims each, at $42,425 in total drug cost. In 2023, CMS named 876 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Shami for performance year 2024, reported as part of a group. Dr. Shami accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 19 papers to Dr. Shami, published from 2007 to 2018. The most frequent topics are Visual Acuity, Diabetic Retinopathy and Laser Coagulation. Dr. Shami has published most often in Am J Ophthalmol. Dr. Shami's most frequent co-authors are Aziz Samir Abdul-Rahim, MD, William L. Benedict, MD and Everett Ai, MD.

Dmand AI links Dr. Shami to 2 clinical trials. Conditions studied include Macular Edema, Vitreous Hemorrhage and Eye Hemorrhage. Jaeb Center for Health Research sponsors the most, 2.

CMS Open Payments shows 106 general payments to Dr. Shami from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $519.

Dmand AI lists 8 awards for Dr. Shami, most recently CMS Stage 1 EHR in 2013.

Dr. Shami graduated from American University of Beirut Faculty of Medicine in 1985. Dr. Shami is a member of AAO.

Dr. Shami is in network with 15 carriers, including Aetna, United Healthcare and Elevance. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.